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A B S T R A C T
Purpose: This study was designed to validate a semi-quantitative clinical assessment tool for cicatrising con-
junctivitis (CC).
Methods: Fifty-ﬁve patients (109 eyes) with mucous membrane pemphigoid (MMP) and 31 patients (61 eyes)
with Stevens-Johnson syndrome (SJS) were included. Three methods were used for validation: (1) comparison of
inter- and intra-observer reproducibility for the components selected for the initial version of the tool, (2)
quantitative measurement of the scarring component with a fornix depth measurer, compared with qualitative
Tauber grading methodology, (3) the ﬁnal version of the tool was compared with the published Sotozono SJS
grading system. Main outcome measures included: inter- and intra-observer reproducibility, calculation of
composite measures of scarring and morbidity, component redundancy, and correlation with other grading
systems.
Results: Inter- and intra-observer agreement was moderate-to-excellent for graded components of conjunctival
hyperaemia, upper and lower symblepharon, upper and lower fornix depth, corneal vascularisation, and corneal
opacity. There was poor-to-good agreement for limitation of motility which was rejected from inclusion in the
ﬁnal tool. Composite scores for scarring components and morbidity components showed good-to-excellent
agreement and distribution of ocular disease severity. Analysis of the composite components showed no re-
dundancy - all components contributed independently. Comparison with both Tauber and Sotozono grading
methodologies showed good concordance.
Conclusions: This study has developed the ﬁrst validated assessment tool applicable to causes of CC. The tool is
concise and discriminates patients with varying disease severity. It measures both disease activity and severity
and is suitable for clinical and research applications.
Introduction
‘Cicatrising conjunctivitis’ (CC) is a term used to describe a het-
erogenous group of disorders that cause inﬂammation and scarring
within the conjunctiva [1]. In countries with a predominantly Cauca-
sian population, such as the United Kingdom, ocular mucous membrane
pemphigoid (MMP) is the commonest cause of CC [2]. Worldwide,
other important causes of CC include Stevens-Johnson syndrome (SJS),
trachoma, atopic keratoconjunctivitis, mechanical or chemical injuries,
ocular rosacea, and Sjogren's syndrome [1,2].
Much of the research into the therapy of CC is focused on the de-
velopment of both anti-inﬂammatory therapies [3,4] and, more re-
cently, anti-scarring therapies [1]. Anti-inﬂammatory therapy is cur-
rently the mainstay of treatment, for which adjunctive conjunctival/
mucosal anti-scarring therapies are at present unavailable but are being
researched [5,6]. Development of new therapies, as well as normal
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clinical practice, ideally requires reproducible inter- and intra-observer
agreement measurement of scarring, inﬂammation, and morbidity (the
sight threatening corneal complications of the disease), using a concise
clinical assessment tool. These measurements are essential to identify
disease progression and the eﬀects of treatments, both for routine
clinical practice and for clinical trials [7]. Currently, no validated tool
exists for these purposes although the requirement for one has been
recognised by the development of 11 methodologies over the last four
decades. Most of these have focused on the evaluation of conjunctival
scarring in MMP [8–14]. These ocular scoring systems have been re-
cently reviewed; the lack of a validated system and their failure to
provide assessments for disease activity as well as damage were high-
lighted [7,15]. Three systems include simple qualitative grading of
conjunctival inﬂammation,[16,17] although one of these does not in-
clude any damage indices [18]
A method for the quantiﬁcation of scarring associated with glau-
coma medications [19] has been subsequently modiﬁed and validated
for use in CC in general [12]. A further system, developed for the as-
sessment of SJS with ocular involvement, incorporates 13 graded
components to measure corneal disease, conjunctival inﬂammation,
and eyelid damage [20]. This system of evaluating the chronic ocular
complications of SJS has been further expanded recently [21]. Only two
of these 11 systems, measuring conjunctival scarring using diﬀerent
quantitative methods, have had both inter- and intra-observer varia-
bility evaluated and have been compared with another methodology.
One has not been used in any studies [13] whereas the other [12], a
fornix depth measurer (FDM), has been used to evaluate the normal
upper and lower fornix depths in both healthy South-Asian [22] and
Caucasian populations [23]. The latter has also been used to assess the
progression of conjunctival scarring in ocular MMP [24].
This study was designed to develop a concise, validated, semi-
quantitative clinical severity assessment tool for CC. This tool in-
corporated the measures of inﬂammation (disease activity), scarring
(disease progression), and morbidity (the sight-threatening eﬀects of
the disease) that are required for diagnosis, measurement of disease
progression, and monitoring responses to treatment, and to have the
sensitivity to discriminate between small diﬀerences in these. Our hy-
pothesis was that a much simpler scoring system, closer in concept to
that of the ﬁve-component trachoma scoring system [25] but with more
subtle grading potential, could be achieved with fewer components
than those demanded by existing grading systems. This hypothesis was
tested through an initial study aimed at determining the inter- and
intra-observer agreement of the components of a new clinical severity
assessment tool. This was followed by an analysis that was used to
eliminate components that could not be reproducibly measured. These
data were used to develop a concise CC clinical assessment tool. This
was further validated by comparison to previously described grading
systems and then prepared in a form ready for use in clinical practice
and clinical trials.
Methods
This was a prospective cross-sectional study on a cohort of patients
diagnosed with ocular MMP and SJS. The study protocol was approved
by the UK National Health Service Research Ethics Committee (REC
Reference 16/LO/0674) and the Singhealth Centralized Institutional
Review Board (CIRB Reference 2017/2270). Informed consent was
obtained from the participants after explanation of the nature of the
study. The study adhered to the tenets of the Declaration of Helsinki.
Patients diagnosed with MMP and SJS with ocular involvement were
identiﬁed from databases of existing patients under the clinical care of
the Corneal and External Diseases department at Moorﬁelds Eye
Hospital NHS Foundation Trust and the Singapore National Eye Centre
respectively.
Patients recruited into the study received two appointments to
evaluate the inter- and intra-observer agreements of two clinical
observers (JKD and HSO) using the clinical assessment tool. JKD is an
experienced Ophthalmologist with over 30 years of clinical practice in
the ﬁeld of corneal and external diseases; at the time of this study, HSO
was a junior Ophthalmologist in a training fellowship in corneal and
external diseases. Patients were examined by both observers at both
visits. The inter-observer interval at each visit was less than 10min. To
avoid changes in clinical status or treatment regimen that could aﬀect
the scores between the two visits, intervals between the two visits for all
patients were within two weeks. Each clinical examiner performed the
assessments independently and was masked to the severity scores
graded by the other clinical examiner. To reduce bias, the severity
scores graded by the examiners in the ﬁrst clinical visit were not
available to the examiners at the second visit.
Designing the clinical assessment tool for cicatrising conjunctivitis
The design of the clinical assessment tool was based upon both the
evaluation of the clinical outcome, reporting from the studies described
above, together with previously described disease activity and damage
indices for ocular surface diseases [7] and the ﬁndings of our cross-
sectional and longitudinal MMP studies [24,26]. It comprised 12
components in three functional categories: a) grading of inﬂammation
(bulbar conjunctival hyperaemia, limbitis), b) grading of scarring (sub-
conjunctival ﬁbrosis, limitation in ocular motility, upper and lower
fornix symblephara, upper and lower fornix depth measure), and c)
grading of ocular morbidity, which are the eﬀects of inﬂammation and
scarring (distichiasis, conjunctival and corneal keratinisation, corneal
vascularisation, corneal opacity).
These 12 components were chosen from the 23 components, in 6
anatomical categories, that were used in our cross-sectional [26] and
longitudinal studies [24], which in common with the Francis [17] and
Sotozono [20,21] systems are the only studies that have graded in-
ﬂammation, scarring, and ocular surface damage. To facilitate the se-
quence and the ﬂow of the examination in the conduct of this validation
study, the tool was converted into a case report form with guidelines for
use (Supplementary Appendix 1).
Following data analyses, a ﬁnalized concise clinical assessment tool
for CC was established (Supplementary Appendix 2). In this ﬁnalized
tool, components in the original tool with inadequate levels of agree-
ment were excluded; although components that were considered im-
portant in the assessment and prognosis in some CC cases, were re-
tained.
Although this study used ocular MMP as the index disease, the tool
has been designed to work with other causes of CC. The ﬁnal version of
the tool was evaluated in SJS, the commonest cause of CC in countries
with predominantly Asian populations and compared with the Sotozono
chronic SJS grading tool [20]. For this study 31 patients (61 eyes)
having SJS were graded using both the ﬁnal version of our CC assess-
ment tool and the Sotozono grading tool.
The assessment of upper and lower central fornix depths
The upper and lower central fornix depths were measured using our
custom-made FDM validated in a previous study [12] and previously
used to establish normal values for the upper and lower fornices in
healthy Caucasians [23] and South-East Asians [22] (Supplementary
Fig. 1; supplementary video). The guidance for the use of the FDM is
found in our ﬁnalized concise clinical assessment tool for CC (Supple-
mentary Appendix 2). Fornix depth measurements were recorded to the
nearest 1 mm.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.jtos.2019.10.010.
To assess the extent of forniceal foreshortening as a marker of se-
verity of conjunctival scarring, the central fornix depths measured were
converted into percentage foreshortening. Published normal age-spe-
ciﬁc values of mean depths of normal fornices were used to calculate
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the percentage foreshortening of the central fornix depths [23]. To
obtain age-adjusted normal values of fornix depths, regression lines
were ﬁtted onto published age-stratiﬁed values; regression equations
were then used to predict the normal values for each age. Thus, fornix
depth percentage foreshortening= [(fornix depth measured – age-ad-
justed normal fornix depth)/age-adjusted normal fornix depth] x 100%.
To facilitate reckoning of fornix depth percentage foreshortening
during clinical assessment, the percentage fornix depth foreshortening
based on age-adjusted normative values were computed into reckoner
tables (Supplementary Appendix 2).
Statistical methods
The statistical software used was Stata v.14.2 (StataCorp, Texas,
USA).
Inter-observer and intra-observer agreement levels
The kappa statistic was estimated for binary clinical data, and the
weighted kappa for ordinal data with more than two categories. For
weighted kappa the linear weights were deﬁned as 1 - |k-j|/|q_max-
q_min|, where k and j refer to the actual ratings and q_max and q_min
are the maximum and minimum of all ratings. The intra-class correla-
tion coeﬃcient (ICC) was used for continuous data, and also for ordinal
data with> 5 categories. A two-way mixed-eﬀects model was used for
estimating ICC, treating eyes (targets) as random, and observers (raters)
as ﬁxed. Other speciﬁcations for the model included the following: a)
unit of analysis used was individual ratings for the eye, and inter-ob-
server and intra-observer agreements were between individual ratings
rather than averages; b) absolute agreements were calculated where
ratings match exactly, rather than consistency of agreements where rat-
ings diﬀered by constant amounts (i.e. perfect correlation, but agree-
ment may be poor). 95% conﬁdence intervals (CI) were calculated for
both kappa statistics and ICC.
Interpretation of agreement levels
The levels of agreement were interpreted from point estimates of
agreement coeﬃcients (kappa statistic and ICC) and their respective
95% conﬁdence bounds. Values < 0.55 were considered ‘poor agree-
ment’; 0.55 to 0.75 considered ‘moderate agreement’; 0.76 to 0.90
considered ‘good agreement’; > 0.90 considered ‘excellent agreement’.
Composite scores
Composite scores were split into two main categories: a) grading of
scarring and b) grading of morbidity (eﬀects of inﬂammation and
scarring). Composite scores were calculated as the sum of scores of
diﬀerent individual components divided by the number of components
within each category. The decision to include an element in the com-
posite score was made based on the interpretation of the level of inter-
observer and intra-observer agreement observed. To obtain the com-
posite scores, the scores of all components included were transposed on
a percentage scale of 0–100. An overall composite score was calculated
by adding the scores of all components in both categories and dividing
Table 1
Characteristics of the study population.
MMP (n=55) SJS (n= 31)
Age of diagnosis in years (range [R], median [M], interquartile range [IQR]) [R] 38–86, [M] 70.0 [R] 19–84, [M] 53.0
[IQR] 60 - 75 [IQR] 34 - 74
Females 29/55 (52.7%) 21/31 (67.7%)
Race
White (British, Irish, other white) 46/55 (83.6%) 0/31 (0%)
Chinese 0/55 (0%) 23/31 (74.2%)
Asian or Asian British (Indian, Pakistani, Blangladeshi, any other South Asian background) 6/55 (10.9%) 2/31 (6.5%)
Malay 0/55 (0%) 4/31 (12.9%)
Black or Black British (Caribbean, African, other black) 1/55 (1.8%) 0/31 (0%)
Other ethinic group 2/55 (3.6%) 2/31 (6.4%)
Previous fornix reconstruction surgery
Yes 10/109 (9.2%) 2/61 (3.3%)
No 99/109 (90.8%) 59/61 (96.7%)
Previous lid surgery
None 69/109 (63.3%) 56/61 (91.8%)
Upper lid entropion repair 11/109 (10.1%) 0/61 (0%)
Lower lid entropion repair 15/109 (13.8%) 0/61 (0%)
Upper lid and lower lid entropion repair 9/109 (8.3%) 0/61 (0%)
Trichiasis surgery 9/109 (8.3%) 4/61 (8.3%)
Ptosis surgery 2/109 (1.8%) 0/61 (0%)
Tarsorrhaphy 1/109 (0.9%) 1/61 (0%)
Vision score
6/7.5 or better 51/109 (46.8%) 26/57 (45.6%)
6/9–6/12 37/109 (33.9%) 14/57 (24.6%)
6/18–6/36 9/109 (8.3%) 9/57 (15.8%)
6/60–2/60 1/109 (0.9%) 1/57 (1.8%)
3/60 – counting ﬁngers only 5/109 (4.6%) 2/57 (3.5%)
Hand movements only 3/109 (2.8%) 5/57 (8.8%)
Perception of light only 1/109 (0.9%) 0/57 (0%)
No perception of light 2/109 (1.8%) 0/57 (0%)
Ocular co-morbidities
None 60/109 (55.0%) 49/61 (80.3%)
Glaucoma/ocular hypertension 10/109 (1.7%) 2/61 (3.3%)
Pseudophakia 30/109 (27.5%) 5/61 (8.2%)
Corneal graft 5/109 (4.6%) 5/61 (8.2%)
Other corneal pathologies 15/109 (13.8%) 1/61 (1.6%)
Retinal diseases 9/109 (8.3%) 2/61 (3.3%)
Uveitis 2/109 (1.8%) 0/61 (0%)
Previous glaucoma surgery 1/109 (0.9%) 0/61 (0%)
Previous vitrectomy 2/109 (1.8%) 0/61 (0%)
MMP Mucous membrane pemphigoid; SJS Stevens-Johnson Syndrome.
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the sum by the total number of components.
To evaluate the internal consistency (reliability) of the composite
score, Cronbach's alpha was estimated together with correlations be-
tween the composite score and each of its constituent components, and
between each constituent component and the remaining components.
Very high values of Cronbach's alpha could indicate some redundancy
in the constituent components when one member of a pair of compo-
nents is highly predictive of the other member. This was also explored.
Comparison between two clinical severity-grading tools
Correlation between the composite scores from our CC clinical as-
sessment tool and the total score from the Sotozono grading tool was
evaluated by calculating the Pearson correlation coeﬃcient. Bland-
Altman plots were used to assess the limits of agreement between the
two grading tools.
Results
Patient characteristics are summarized in Table 1.
MMP patients. A total of 55 patients (109 eyes) with a diagnosis of
ocular MMP were recruited. Two patients were unable to attend the
second assessment visit. Of these, one patient had a corneal epithelial
defect following the ﬁrst clinical visit, which may have resulted from
topical anesthetic toxicity and/or trauma when measuring the fornix
depth. The median age of patients was 70.0 years (interquartile range
(IQR) 60–75); 29/55 (52.7%) of patients were female; 46/55 (83.6%)
were of Caucasian origin. In this series of MMP patients, 34/55 (61.8%)
were direct immunoﬂuorescence (DIF) positive and 20/55 (36.4%)
were DIF negative. DIF investigation was not performed in one patient.
The diagnosis of MMP in those without a positive DIF status was based
on our previously described diagnostic criteria of ‘DIF negative MMP’
[26]
SJS patients. Thirty-one patients (61 eyes) with a diagnosis of SJS
with ocular involvement were recruited having a median age of 53.0
years (IQR 34–74); 21/31 (67.7%) of patients were female; 23/31
(74.2%) were of Chinese origin.
Inter-observer and intra-observer agreement
Table 2 lists the inter-observer and intra-observer point estimates of
agreement coeﬃcients for each individual component of the severity-
grading tool and their corresponding levels of agreement. Of the 12
components in the three categories of the assessment tool, moderate to
excellent levels of agreements were found for the following 7 compo-
nents:
a) Inﬂammation category: bulbar conjunctival hyperaemia
b) Scarring category: lower fornix depth percentage foreshortening,
upper fornix depth percentage foreshortening, lower fornix sym-
blepharon score, and upper fornix symblepharon score
c) Morbidity category: corneal vascularisation and corneal opacity
grading
These parameters were included in the ﬁnal version of the CC as-
sessment tool (Supplementary Appendix 2).
Due to the wide conﬁdence intervals of the agreement levels for
these components, inadequate levels of agreement were observed for
the following 2 components: limitation in motility (scarring category)
and ocular surface keratinisation (morbidity category). Limitation in
motility (scarring category) was left out of the ﬁnal tool. Ocular surface
keratinisation (morbidity category) however, was retained (but not
scored). The tool includes the identiﬁcation of conjunctival keratini-
sation, lid margin/tarsal conjunctival keratinisation, and corneal kera-
tinisation. The presence of ocular surface keratin has been shown in
previous studies to be an important marker of severe dry eyes and
overall disease severity in ocular surface disorders [17,20,27,28].
Furthermore, in SJS the presence of lid margin keratinisation is thought
to be a causative factor for poor visual prognosis [27,29]. Three further
components, limbitis (inﬂammation category), subconjunctival ﬁbrosis
(scarring category), and distichiasis (morbidity category), were also not
scored but have been retained in the ﬁnal assessment tool because of
their clinical importance in the assessment of individual cases. Limbitis
is an important prognostic sign when present in severe conjunctival
inﬂammation but was absent in our subjects. Subconjunctival ﬁbrosis
was identiﬁed in 98% of cases and, as a result, not analysed but has
been retained as being important in the diagnosis of early CC. Dis-
tichiasis is relatively rare in MMP, used as the index disease for inter-
and intra-observer evaluation of the tool in this study, but is an im-
portant sign of ocular surface scarring, particular in SJS.
This gives a total of 11 components used in the ﬁnal assessment tool
(Supplementary Appendix 2).
Table 2
Inter-observer and intra-observer agreements of the individual components of
the clinical severity-grading tool.
Component Statistica Point
estimate
95% CI Agreement
level
INFLAMMATION
Bulbar conjunctival
hyperaemia
Between Observer ICC 0.88 0.84 0.90 Good
Within Observer ICC 0.76 0.69 0.81 Moderate to
Good
Limbitis Not analysed (absent in all eyes in this study)
SCARRING
Limitation in motility
Between Observer kappa 0.49 0.23 0.74 Poor
Within Observer kappa 0.72 0.51 0.93 Poor to Good
Lower fornix symblepharon
Between Observer kappa 0.71 0.63 0.79 Moderate to
Good
Within Observer kappa 0.74 0.60 0.82 Moderate to
Good
Upper fornix symblepharon
Between Observer kappa 0.68 0.59 0.78 Moderate to
Good
Within Observer kappa 0.66 0.55 0.77 Moderate to
Good
Lower fornix depth percentage foreshortening (%)b
Between Observer ICC 0.93 0.91 0.95 Excellent
Within Observer ICC 0.94 0.92 0.95 Excellent
Upper fornix depth percentage foreshortening (%)b
Between Observer ICC 0.89 0.81 0.93 Good to
Excellent
Within Observer ICC 0.92 0.89 0.94 Good to
Excellent
Subconjunctival
ﬁbrosis
Not analysed (present in 98% of eyes in this study)
MORBIDITY (EFFECTS OF INFLAMMATION AND SCARRING)
Distichiasis Not analysed (only two eyes aﬀected in this study)
Ocular surface keratinisation
Between Observer kappa 0.59 0.43 0.75 Poor to Good
Within Observer kappa 0.64 0.49 0.79 Poor to Good
Corneal vascularisation
Between Observer kappa 0.76 0.71 0.82 Moderate to
Good
Within Observer kappa 0.80 0.75 0.85 Moderate to
Good
Corneal opacity
Between Observer ICC 0.84 0.79 0.87 Good
Within Observer ICC 0.89 0.86 0.92 Good to
Excellent
CI= conﬁdence interval, ICC=Intraclass corrrelation coeﬃcient.
a Kappa statistic was estimated for ordinal data with ≤5 categories and ICC
for continuous data or ordinal data with>5 categories.
b Fornix depth percentage foreshortening = (Normal age-adjusted fornix
depth – measured fornix depth)/(Normal age-adjusted fornix depth) x 100.
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Composite scores
Visible inﬂammation in CC is a marker of ‘activity’ and is thus
variable, and reversible. This has not been included in a composite
scoring for conjunctival scarring, but has been included in the ﬁnal tool
as an index of reversible disease activity for monitoring response to
immunosuppressive treatment. The aim of cicatrising conjunctivitis
composite scores are to fully describe the scarring and morbidity ca-
tegories of the assessment tool, both of which were represented by more
than one component. Of the seven components with moderate-to-ex-
cellent agreement retained in the ﬁnal version of the assessment tool,
six components were used to calculate composite scores.
Composite score – grading of scarring
This comprised four components: upper fornix symblepharon score,
lower fornix symblepharon score, upper fornix depth percentage fore-
shortening, and lower fornix depth percentage foreshortening. The
composite score for the grading of scarring was calculated as a sum of
all the following scores divided by 4. Both upper and lower sym-
blepharon scores of 0–2 were transposed into a 0–100 scale by [sym-
blepharon score] x 100/2. The upper and lower fornix depth percentage
foreshortening were already in a 0–100 scale so that no transposition
was required. There was excellent inter-observer agreement (ICC 0.93,
95% CI 0.91–0.94) and intra-observer agreement (ICC 0.93, 95% CI
0.91–0.94) for the composite scarring grading. This is summarized in
Table 3.
Composite score – grading of morbidity
This comprised of two components: the corneal vascularisation
score and corneal opacity scores. The composite score was calculated as
a sum of the following scores divided by 2. The corneal vascularisation
grading scores of 0–5 were transposed into a 0–100 scale by [corneal
vascularisation grading score] x 100/5. The corneal opacity grading
scores of 0–9 were transposed into a 0–100 scale by [corneal opacity
grading score] x 100/9. There was good to excellent inter-observer
agreement (ICC 0.92, 95% CI 0.89–0.94) and excellent intra-observer
agreement (ICC 0.95, 95% CI 0.93–0.976) for the composite score on
grading of morbidity. This is summarized in Table 3.
Composite score – combined scarring and morbidity categories
This combined score has the potential to provide one number that
can quantify the largely irreversible eﬀects of the disease both for
routine clinical follow-up and in prospective studies. This combined
score was evaluated to establish whether a score for any one of the six
constituent components might predict the score of another indicating
redundancy of one or more components. The results of this analysis are
described in Table 4, which summarizes the results of inter-component
correlations, correlations between components of the two main cate-
gories (scarring and morbidity) and the overall composite score, and
the internal consistency of the overall composite score. The component-
rest of components correlation is an assessment of redundancy. The
correlations between each component and the remaining components
were poor to moderate, between r= 0.59 (lower fornix symblepharon)
and r= 0.73 (corneal vascularisation score). This assessment of re-
dundancy indicates that, when pairs of components were compared,
one component does not have the potential to adequately predict the
other such that each of the components contributes important addi-
tional information to the overall severity-grading tool. This was con-
ﬁrmed by the good internal consistency of the overall composite score
(Cronbach's alpha=0.845), which could not be improved by dropping
any one of the 6 components; as a result, all these components were
retained in the ﬁnal CC assessment tool.
Frequency distributions of inﬂammation and composite grading for MMP
ocular disease
Fig. 1 describes the distribution of the 109 eyes in the validation
study by their inﬂammation and composite scores.
Practical examples and applications
Table 5 shows examples of the practical use of the CC assessment
tool for patients from this series [26]. Supplementary Appendix 2
provides the ﬁnalized CC assessment tool and guidelines for its use in
clinical and research settings. It also provides ready reckoners to
identify age adjusted percentage reduction for both upper and lower
fornix depth measurements. Supplementary Appendix 3 is a spread-
sheet calculator, which provides individual and composite scores for
the three functional categories of inﬂammation, scarring and morbidity;
it is envisaged that this calculator will be used for calculation in clinical
studies rather than for clinical use. It should be noted that the com-
ponents of limbitis, subconjunctival ﬁbrosis, distichiasis, and ocular
surface keratinisation are to be recorded because of their diagnostic or
prognostic importance in the ﬁnalized CC assessment tool but not
scored. This has been done because there was poor inter- and intra-
observer variability for keratinisation whereas for the other signs, the
inter- and intra-observer agreements could not be assessed. Users of the
tool may decide to score these components in clinical practice or re-
search. However, in the absence of new data, the user must understand
that the scoring of these components may not be reproducible by an-
other observer.
Table 3
Inter-observer and intra-observer agreements of the composite scores in each category: scarring, morbidity (eﬀects of inﬂammation and scarring), and overall
composite score.
Composite Scores Statistic Point estimate 95% CI Agreement level
i) Scarring score (%)a
Between Observer Agreement ICC 0.93 0.91 0.94 Excellent
Within Observer Agreement ICC 0.93 0.91 0.94 Excellent
ii) Morbidity score (%)b
Between Observer Agreement ICC 0.92 0.89 0.94 Good to Excellent
Within Observer Agreement ICC 0.95 0.93 0.96 Excellent
Overall Composite (Scarring & Morbidity) score (%)c
Between Observer Agreement ICC 0.95 0.93 0.96 Excellent
Within Observer Agreement ICC 0.96 0.94 0.97 Excellent
CI= conﬁdence interval, ICC= intraclass correlation coeﬃcient.
a Composite score for scarring comprises of a) lower fornix depth percentage foreshortening, b) upper fornix depth percentage foreshortening, c) percentage lower
fornix symblepharon, and d) percentage upper fornix symblepharon.
b Composite score for morbidity (eﬀects of inﬂammation and scarring) comprises of a) corneal vascularisation, and b) corneal opacity.
c Overall composite score comprising of all elements in the scarring and morbidity composite scores.
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Comparison of the CC assessment tool with the Sotozono grading system for
chronic SJS
These were compared in a cohort of 31 patients with ocular in-
volvement by SJS. Good correlation was found between the composite
score of our CC assessment tool and the total Sotozono score [Pearson r
0.93 p < 0.001] [Fig. 2a]. No signiﬁcant proportional bias was also
observed when Bland-Altman plots were applied [Fig. 2b].
Discussion
This study has developed an assessment tool for CC. It has been
developed from previously described tools for ocular MMP and SJS
(compared in Supplementary Table 1) and then modiﬁed following the
calculation of inter- and intra-observer levels of agreement, so as to
include only those components that can be reproducibly scored and
which show no redundancy (the presence of one does not predict the
presence or severity of another). Instead of using anatomical categories,
this tool focuses on three functional categories of inﬂammation (an
indicator of disease activity) together with scarring and morbidity (both
indicators of disease damage) that result from CC. This is unlike most
previous assessment tools that have focused on scarring alone [15].
These functional categories are important measures needed for both
clinical assessments and for clinical trials. The diﬀerent categories of
Table 4
Inter-component correlation, component-composite correlation, and internal consistency of overall composite scores of scarring and morbidity categories.
Components of score
Observations Component-
Composite
Correlationa
Component-rest of components
correlationb
Average inter-component
covariancec
Cronbach's alphad
Lower fornix symblepharon 109 0.718 0.585 470.846 0.827
Upper fornix symblepharon 109 0.761 0.677 491.416 0.818
Lower fornix depth percentage
foreshortening
109 0.755 0.612 437.755 0.824
Upper fornix depth percentage
foreshortening
109 0.713 0.596 487.069 0.826
Corneal vascularisation 109 0.832 0.729 404.900 0.798
Corneal opacity 109 0.763 0.617 428.765 0.824
Overall Composite score 453.456 0.845
a Correlation between the component and the composite score.
b Correlation between the component and all the remaining components combined.
c Average covariance when the component is dropped in calculation of composite score.
d Chronbach's alpha value when the component is dropped in calculation of composite score.
Fig. 1. Frequency distribution of composite scores a) Inﬂammation score b) Scarring score c) Morbidity score d) Composite score combing scarring and morbidity
scores.
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the tool can be used independently. For example, conjunctival hyper-
emia is a marker for conjunctival inﬂammation, which is an important
disease activity marker and a principal short-term target for therapy;
inﬂammation is easily assessed at every visit. Published inﬂammation
grading schemes have used entirely subjective evaluation of con-
junctival hyperaemia [20,28], whereas ours described in this study is
guided by a comparison to standard panel of photographs and has good
inter-observer agreement. The only moderate-to-good intra-observer
agreement for this component may be partly explained by diﬀerences in
the degree of hyperemia between the ﬁrst and second assessments.
Supplementary Table 1 summarizes the comparison of our tool to
three other published tools for the assessment of diﬀerent types of CC
(other than trachoma) and shows that our tool has fewer categories and
Table 5
Examples of the use of the cicatrising conjunctivitis grading tool for individual
patients.
Patient study #1 Aged 86, Right Eye
Categories Components Raw value Transposition Percentage
Inﬂammation 1
Inﬂammation
3 3/16 x 100 18.8
Inﬂammation score (total of percentage value) 18.8%
Limbitis: No
Scarring 2 Lower fornix
depth
2 80.2%
3 Upper fornix
depth
14 6.7%
4 Lower
symblepharon
1 1/2 x 100 50%
5 Upper
symblepharon
0 0 0%
Scarring score (total of percentage values/4) 34.2%
Morbidity 6 Corneal
vascularity
3 peripheral
0 central
3/5 x 100 60%
7 Corneal
opacity
2 peripheral
0 central
2/9 x 100 22%
Morbidity score (total of percentage values/2) 41%
Distichiasis: No
Keratinisation: No
Combined scarring & morbidity score (total of percentage values/6) 36.5%
Patient study #2 Aged 68, Right Eye
Categories Components Value Transposition Percentage
Inﬂammation 1
Inﬂammation
9 9/16 x 100 56%
Inﬂammation score (total of percentage value) 56%
Limbitis: No
Scarring 2 Lower fornix
depth
4 63.2%
3 Upper fornix
depth
3 80.5%
4 Lower
symblepharon
1 1/2 x 100 50%
5 Upper
symblepharon
1 1/2 x 100 50%
Scarring score (total of percentage values/4) 60.9%
Morbidity 6 Corneal
vascularity
4 peripheral
0 central
4/5 x 100 80%
7 Corneal
opacity
4 peripheral
1 central
9/9 x 100 100%
Morbidity score (total of percentage values/2) 90%
Distichiasis: No
Keratinisation: No
Combined scarring & morbidity score (total of percentage values/6) 68.8%
Patient (hypothetical case with burned out disease no inﬂammation,
with ankyloblepharon, central vascularisation and opacity Aged 68,
Right Eye)
Categories Components Value Transposition Percentage
Inﬂammation 1 Inﬂammation 0/16 0%
Inﬂammation score (total of percentage values) 0%
Limbitis: No
Scarring 2 Lower fornix
depth
0 100%
3 Upper fornix
depth
0 100%
4 Lower
symblepharon
2 2/2 x 100 100%
5 Upper
symblepharon
2 2/2 x 100 100%
Scarring score (total of percentage values/4) 100%
Morbidity 6 Corneal
vascularity
4 peripheral
1 central
5/5 x 100 100%
Table 5 (continued)
Patient (hypothetical case with burned out disease no inﬂammation,
with ankyloblepharon, central vascularisation and opacity Aged 68,
Right Eye)
Categories Components Value Transposition Percentage
7 Corneal
opacity
4 peripheral
1 central
9/9 x 100 100%
Morbidity score (total of percentage values/2) 100%
Distichiasis: No
Keratinisation
- Bulbar conjunctiva: Yes
- Lid margin/tarsal conjunctiva: Yes
- Cornea: No
Combined scarring & morbidity score (total of percentage values/6) 100%
Fig. 2. Comparison of the studied clinical severity-grading tool with the
Sotozono grading system for Stevens-Johnson Syndrome. a) Good correlation
was found between the composite scores from our cicatrising conjunctivitis
assessment tool and the total scores from the Sotozono grading system [Pearson
r=0.93 p < 0.001]; b) no signiﬁcant proportional bias between the two
grading systems was also observed when Bland-Altman plots were applied.
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components. The rationale for excluding some of the components used
in other schemes is as follows. We chose the components for mea-
surement based on our experience of parameters that were reliably
measurable in our cross-sectional study [26]. Of the components used
by Francis [17] we omitted: entropion because patients have often had
multiple surgeries altering the lid position, trichiasis as lashes may have
been recently epilated, lagophthalmos which is diﬃcult to identify
unless severe, Schirmer's test because patients with short fornices
cannot have this measured, ocular rotations as we found poor inter- and
intra-observer correlation in our analysis, punctate keratopathy as it is
present in most cases and time consuming to assess, corneal epithelial
defect/ulceration and infection as these are of short duration and their
eﬀects are measured by the degree of residual corneal opaciﬁcation
which we assessed, and lastly visual acuity. Visual acuity is an unreli-
able measure of the severity of CC because many of the patients have
other causes of visual loss that may be hard to identify and quantify in
the setting of loss of corneal translucency. By comparison with the
Sotozono grading system [20], in addition to leaving out the above
mentioned components, we left out mucocutaneous junction, meibo-
mian gland disease, punctal and palisade of Vogt grading, as being
potentially diﬃcult to measure reliably, and unlikely to add to the
ability to discriminate between cases using the reduced numbers of
components that we ﬁnally selected. We also left out conjunctivalisa-
tion because of the diﬃcultly our observers found in distinguishing this
from corneal neovascularisation in our previous cross-sectional study
[26]. The comparison of our CC assessment tool to the Sotozono
grading system in SJS showed good correlation and agreement [Fig. 2],
despite a 50% reduction in the number of components graded (from 14
to 7) in our tool.
Scarring is a functional category, which is a hallmark sign of ocular
MMP, resulting in much of the disease morbidity, and as such has to
date, been the only category measured in many MMP grading systems.
Most of these systems rely upon subjective grading of scarring usually
restricted to lower fornix shortening and symblepharon. The most
widely used for clinical studies and trials were developed three decades
ago. Mondino and Brown described a four stage grading system in
which the percentage shrinkage of the lower fornix was qualitatively
evaluated [8]. Foster subsequently described a diﬀerent four stage
qualitative system which included sub-epithelial ﬁbrosis without fornix
shortening (the earliest sign of CC) as Stage I, and diﬀerentiated 3
subsequent stages by the presence of fornix foreshortening (Stage II),
presence or absence of symblepharon (Stage III), and ankyloblepharon
(Stage IV) [9]. These methods can often be used to retrospectively grade
disease from clinical records. However, Tauber and Foster recognised
that for the assessment of progression of scarring, both of these methods
were relatively insensitive in detecting disease progression. To remedy
this, they described a qualitative system combining four grades of
fornix foreshortening with four grades of horizontal involvement by
symblepharon, resulting in a 10 stage system, further subdivided by the
number of discrete symblephara when these are present [10]. However,
this number of symblephara is not discrete but variable depending on
the degree of traction on the lower lid. Although these grading systems
have been the most widely used to date [15,16], their assessment of
scarring are qualitative, depending on subjective assessment, and lim-
ited to the assessment of the lower conjunctival fornix. Studies have
indicated that subjective measures to evaluate scarring are not as good
as objective measures [12]. Recognising the limitations of these
methods, various groups have since introduced devices to facilitate the
objective evaluation of the conjunctival fornices [11,12,19,22,23].
Such devices include the FDM, which allow quantitative measurements
of the lower, and in some devices, the upper forniceal depths. We have
used an FDM which reproducibly measures inter- and intra-observer
variability within± 1mm for the lower fornix, giving intra-observer
agreement to within±1mm for 86% of measurements compared to
only 63% for the subjective measurements [12]. The 95% conﬁdence
limits for the upper fornix were±2.5mm. Furthermore, this device has
also been used to deﬁne the upper and lower fornix depths in normal
Caucasian [23] and South Asian [22] populations which are invaluable
for detecting fornix depths that indicate early CC and which we have
incorporated into our tool. Our published phenotype comparison cross-
sectional study incorporates the use of both the FDM and the Tauber
staging for the evaluation of scarring [26], the latter of which has been
considered the ‘gold standard’ for the grading of conjunctival scarring
[10]. In our study, we found good correlation between the lower fornix
depth measurements and Tauber staging (Spearman's r=−0.874,
p < 0.001) (Supplementary Fig. 2). However, this does not infer that
the inter- and intra-observer agreements are as good for the Tauber
system as described above. The FDM device is shortly to become
commercially available as an inexpensive disposable device (http://
www.scopeophthalmics.com/fdm, Scope Ophthalmics Ltd, United
Kingdom); FDM availability has been a principal deterrent to its
widespread adoption because of the expense of in-house production and
inadvertent disposal of the device in clinics.
Our ﬁnal CC assessment tool, together with ready reckoners and
calculators, is provided in Supplementary Appendices 2 and 3. We think
that the three categories of our tool will be used independently in dif-
ferent applications. For clinical use, the inﬂammation category assess-
ment takes only a few minutes to grade. Being reproducible, we hope
that this category might be used in all specialist clinics treating patients
with anterior segment inﬂammatory diseases who wish to assess the
responses to anti-inﬂammatory treatments. The scarring category as-
sessment with the FDM and ready reckoner for the lower fornix also
takes only a few minutes and will identify patients with scarring dis-
eases of the conjunctiva. For example, they can be used in glaucoma
clinics where conjunctival scarring is a common side eﬀect of medica-
tion, in general ophthalmology clinics for the assessment of those with
chronic conjunctivitis to identify those with signiﬁcant scarring earlier
in the course of disease, and in oculoplastics surgery clinics where
patients with entropion due to CC are often initially misdiagnosed. The
morbidity category assessment aims to identify patients who suﬀer from
the sight-threatening complications of inﬂammation and scarring.
Components in this category include an evaluation of the presence or
absence of ocular surface keratinisation, distichiasis, and corneal
pathologies (vascularisation and opaciﬁcation). These measures convey
an indication of the overall severity of ocular surface disease and visual
prognosis. Such information can also be used for epidemiological stu-
dies, assessment of treatment outcomes, as well as a guide to when
visual rehabilitative therapy is needed.
Ocular surface keratinisation deserves a special mention. The pre-
sence of keratin on the ocular surface (conjunctiva, lid margin, and
cornea), has been shown in previous studies to be an important marker
of the severity of dry eye and ocular surface damage [17,20,27,28]. In
SJS the presence of lid margin keratinisation is a direct causative factor
of poor visual prognosis [27,29]. The damage from lid margin kerati-
nisation is thought to be through a vicious cycle of blink-related mi-
crotrauma to the ocular surface resulting in chronic inﬂammation and
eventually scarring. Indeed, the presence of lid margin involvement
may be an indication for speciﬁc treatments, both in the acute phase
(e.g. amniotic membrane graft) [27] and chronic phase (e.g. mucous
membrane graft) [29]. Thus, despite poor levels of inter- and intra-
observer agreement for the ocular surface keratinisation grading found
in our study, its identiﬁcation has been retained in the ﬁnal clinical
assessment tool.
The key limitations of this study are that the examiners might have
potentially recalled their previous measurements when carrying out the
second examination in the part of the study that evaluated intra-ob-
server repeatability. Also, although designed for use in any disease
causing CC, the tool has only been evaluated in patients with MMP and
SJS. Further studies are required to evaluate its usability in other causes
of CC. The validation of this clinical assessment tool was performed
using a cross-sectional design. A longitudinal design of inter-observer
and intra-observer assessments on the same cohort of patients may give
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information on the robustness of this clinical assessment tool in re-
peated measurements at diﬀerent time points to monitor disease pro-
gression. However, as many CC conditions progress over long periods of
time (months to years), it was beyond the scope of this study to perform
such longitudinal validation studies.
Nevertheless, there are a number of strengths: (i) the adoption of the
FDM to quantify fornix scarring which shows better inter- and intra-
observer agreement than the widely used qualitative Tauber system
[10,12], but with which it correlates well for the assessment of fornix
foreshortening, (ii) the choice of components for the ﬁnal tool by
evaluation of those used in other studies [26] (iii) reﬁnement of these
components by rejecting those having poor inter- and intra-observer
agreement (iv) the exclusion of redundancy between the remaining
components (v) the comparison of this reﬁned tool with the Sotozono
grading system [20] showing similar case discrimination using fewer
components. The principal utility of this CC assessment tool is the
minimal number of components that have to be measured to provide an
adequate evaluation of a patient with CC in a clinical setting, resulting
in a tool that takes an experienced user only 10min to perform or less,
for measurement of individual categories of disease eﬀects.
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